morning welcome scientific fourth quarter earn call operator instruction today presentation opportunity question please note event record would like turn conference vice president investor relation please ahead vice president investor relation thank hello everyone thank join today call chairman chief executive officer executive vice president chief financial officer issue press release earlier morning announce result include reconciliation measure release post copy release reconciliation measure today call investor relation section website head financials file duration morning call approximately hour focus comment performance future catalyst outlook business include full year guidance review financials quarter provide detail regard full year guidance take question today session join chief medical officer begin like remind everyone call operational revenue growth exclude impact foreign currency fluctuation organic revenue growth exclude acquisition divestiture full period comparable sale relevant acquisition organic growth versus include close march respectively interventional medicine close respectively divestiture include spec pharma close march global embolic microspheres portfolio intrauterine health franchise divest second quarter respectively throughout call today refer growth rate versus utilize comparison last full year baseline prior forward guidance correspond result compare guidance exclude medical acquisition expect close information please refer slide financial operate highlight deck find investor relation website call reference sale revenue unless otherwise specify organic call contain forward look statement within mean federal security identify word like anticipate expect believe estimate similar word include among thing impact pandemic upon company operation financial result statement growth market share product approval launch acquisition clinical trial save growth opportunity cash flow expect financial performance include sale margin earn rate spend expense factor cause difference include describe risk factor section recent subsequent file statement speak today date disclaim intention obligation update point turn comment chairman chief executive officer thank thank everyone join today proud agility spirit employee continue impress resiliency hospital system ability provide patient care need pandemic please strength fourth quarter performance anticipate business unit either maintain gain share quarter despite challenge present full year basis global strength product diversification category leadership strategy result business exception gain share look forward year ahead remain bullish near term longer term opportunity investor fourth quarter total company operational sale grow versus organic sale grow achieve high guidance range fourth quarter organic sale grow versus full year operational sale grow versus organic sale grow achieve high guidance range full year organic sale grow versus adjust grow versus flat achieve high guidance range full year adjust grow versus versus exceed high full year guidance range fourth quarter adjust operate margin result second half rate full year adjust operate margin overall please cash flow full year free cash flow generation billion adjust free cash flow billion grow versus turn anticipate impact underlie procedure full year versus provide wider range account uncertainty relate wave staff shortage first quarter organic revenue guide growth full year exclude acquisition expect close first quarter adjust estimate expect full year adjust despite near term macroeconomic pressure continue target operate margin expansion goal double digit adjust growth high range provide detail sale performance outlook include insight provide highlight full year result along comment outlook regionally operational basis grow versus fourth quarter full year full year grow inclusive basis point tailwind acquisition continue strength product launch across portfolio middle east grow operational basis versus fourth quarter full year continue strong performance despite pandemic impact many western country excellent growth middle east region full year basis business unit grow double digit versus prior year majority business gain share continue anticipate strong growth region give innovative product pipeline globalization effort integration acquisition grow operationally versus fourth quarter full year within quarter vast majority country grow versus prior year double digit growth support ongoing product launch full year grow fuel product like ranger innovative launch across coronary therapy portfolio provide additional comment business unit urology public health sale grow organic basis versus fourth quarter full year basis grow versus versus within quarter grow double digit please improve reimbursement hospital outpatient full year basis strength across business double digit growth core stone restoration look forward toward remain excite strong leadership position extend acquisition market lead laser technology turn endoscopy sale grow organically versus fourth quarter full year growth versus versus duration year broad base strength across region franchise result endoscopy business achieve billion within quarter launch stent full year basis grow product line globally remain excite outlook innovative offer within single image portfolio include model model discover look continue anticipate market growth endoscopy global commercial continue execute high level create long term partnership hospital give unique breadth differentiation portfolio turn organic sale grow versus fourth quarter full year sale grow versus decline versus high voltage business grow single digit expect line market improve sequential growth franchise enable enhance electrode launch pacer business grow single digit likely line market first patient modular trial dual track clinical study stand alone leadless pacemaker provide pace patient within diagnostics franchise implantable cardiac monitor continue perform grow share business grow full year forma basis enable differentiate portfolio strong execution electrophysiology sale grow versus fourth quarter organic basis full year growth versus versus importantly international sale grow versus prior full year operational basis fuel innovative portfolio include early launch physician enthusiastic safety ease technology excite outlook business look forward complement close first quarter neuromodulation fourth quarter organic revenue grow versus prior year full year sale grow versus flat despite wave impact procedure volume continue gain share strong demand alpha system ongoing clinical evidence result full year growth rate versus week present various data include year combo data support longevity therapy continue roll trial study system treatment patient chronic back pain undergo spinal surgery anticipate initial clinical work come month brain franchise impact procedure volume continue enhance portfolio capability strong full year growth versus look forward expand offer partnership interventional cardiology organic sale grow versus fourth quarter versus full year include tailwind approximately basis point relate sale return reserve transition consignment full year interventional cardiology sale grow versus coronary therapy complex franchise strong growth strength across every region enable recent launch guidance system within drug stent continue differentiate portfolio global launch synergy millimeter continue anticipate first market agent drug coat balloon expect complete enrollment trial first half extremely please performance franchise fourth quarter sale surpass expectation importantly global performance consistent quarter strong double digit growth result full year sale million grow versus continue please ability deliver safest efficient therapy increase physician utilization global expansion drive greater awareness grow market clinical evidence generation remain important focus expect first readout ongoing analysis registry later month analysis include patient largest data patient present date continue expect significant growth driver scientific beyond across structural heart franchise highest quarterly sale result date continue perform positive physician feedback clinical performance ease valve excite year share across full market approach share open account please early clinical progress military technology decide discontinue work military program time financial investment require commercialize platform compare near long term portfolio opportunity across company make decision focus execution exist future technology within structural heart space elsewhere within portfolio peripheral intervention organic sale grow versus fourth quarter full year sale growth versus versus within drug portfolio please globalization ongoing clinical evidence support ranger result exceed sale goal million venous market lead varicose vein offer grow continue runway underserved market close acquisition look forward launch arterial venous offer second half complement broader portfolio extend category leadership interventional cardiology grow full year basis support ongoing clinical evidence include trial first positive phase trial study second line therapy patient liver dominant fail first line chemotherapy focus improve patient health come responsibility positive impact world share environmental social governance practice guide make long term measurable progress proud announce scientific receive catalyst award premier recognition organization initiative advance woman workplace scientific also rank company contribution create provide benefit work life balance cultivate diverse inclusive workplace produce sustainable product build stronger community grateful passion commitment global continue deliver value part create better future global business global corporate citizen face challenge last year stronger build capability enable better serve patient customer today future position category lead innovative product position continue focus investment clinical evidence continue enter high growth adjacent market acquire several company past year innovative product accretive market continue evolve leadership commercial structure best enable excite technology remain commit long term financial goal organic revenue growth operate margin expansion double digit adjust growth strong cash flow generation grateful employee spirit turn thing review financial performance forward look expectation executive vice president chief financial officer thank fourth quarter consolidate revenue billion represent report revenue growth versus fourth quarter reflect million headwind foreign exchange operational basis revenue growth quarter sale acquisition contribute basis point partially offset divestiture specialty pharmaceutical business result organic revenue growth toward high guidance range growth versus growth include basis point tailwind sale return reserve recognize contemplate guidance compare fourth quarter organic revenue growth nicely midpoint guidance range growth exclude million sale divest intrauterine health specialty pharmaceutical business million sale acquire business include adjust earn share represent growth versus flat versus achieve high guidance range drive revenue performance higher guidance range slightly favorable adjust rate full year consolidate revenue billion represent report revenue growth versus full year reflect million tailwind foreign exchange operational basis revenue growth quarter versus sale acquisition contribute basis point offset sale divest intrauterine health specialty pharmaceutical business result organic revenue growth within guidance range compare full year organic growth midpoint guidance range growth exclude million sale divest business million sale acquire business include interventional medicine million specialty pharmaceutical sale prior divestiture full year adjust earn share represent growth versus growth versus exceed high guidance range adjust gross margin fourth quarter line expectation slight sequential improvement record continue face macro environment headwind gross margin include plant specific measure increase freight price pressure higher direct labor wage omicron variant surge increase headwind particularly higher level relate absenteeism plant price pressure direct material drive unfavorable manufacture variance reminder manufacture variance capitalize balance sheet realize approximate month period result expect full year gross margin improve slightly versus second half gross margin first half expect second half drive impact unfavorable manufacture branch capitalize balance sheet typical standard revaluation line historical trend anticipate second half gross margin improve versus first half drive lower relate headwind recognition full standard improvement longer term goal remain return gross margin level plus global supply chain disruption inflation lessen time fourth quarter adjust operate margin result second half average full year adjust operate margin light increase gross margin pressure felt prudent provide range adjust operate margin expect full year within range represent basis point improvement full year high represent long range plan goal basis point annual improvement versus second half average basis fourth quarter operate margin include million intangible asset impairment relate discontinuation program outline million litigation relate expense provide detail moment move line adjust interest expense total million million full year line expectation fourth quarter rate adjust basis full year adjust rate include discrete item benefit stock compensation account exclude item operational rate favorable expectation drive geographic earn fully dilute weight average share outstanding billion share billion share full year adjust free cash flow quarter million free cash flow million million operate activity million capital expenditure full year deliver adjust free cash flow billion free cash flow billion billion operate activity million capital expenditure exceed expectation full year adjust free cash flow growth versus drive lower work capital balance increase inventory position sale recovery finish year favorable adjust free cash flow continue invest inventory relate impact manufacture labor direct material availability cash hand billion continue expect close acquisition medical fund cash hand priority capital remain high quality tuck continue opportunity conjunction financial goal respect legal reserve book million include million relate ongoing litigation neuromodulation space million relate mesh product liability claim material change outlook mesh claim last three year materially claim remain settle continue seek prompt resolution active case claim total legal reserve million walk guidance full year reminder guidance include acquisition medical since close expect full year operational revenue growth range versus exclude approximate basis point headwind foreign exchange base current rate include basis point contribution acquisition million divestiture specialty pharmaceutical sale exclude impact close acquisition divestiture expect full year organic revenue growth range versus expect first quarter operational revenue growth range versus exclude approximate basis point headwind foreign exchange base current rate include basis point contribution acquisition million specialty pharmaceutical sale exclude impact close acquisition divestiture expect first quarter organic revenue growth range versus forecast full year operational rate approximately adjust rate include benefit account standard stock compensation note forecast rate include headwind delay provision take effect relate treatment expenditure believe bipartisan support reverse provision legislation enact would expect rate revert historic range approximately operational adjust expect adjust earn share full year range first quarter range item keep mind look model expect line expense include interest payment dilution portfolio associate hedge program approximately million year prefer stock dividend approximately million year expect fully dilute weight average share count approximately billion share billion share full year please check investor relation website financial operational highlight outline detail result turn back moderate vice president investor relation thank open question next minute operator instruction please ahead